CAU
DGX icon

Caxton Associates (UK)’s Quest Diagnostics DGX Stock Holding History

Caxton Associates (UK)’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3,528
Closed -$672K – 808
2025
Q3 		$672K Buy
+3,528
New +$626K 0.02% 406
2025
Q2 		– Sell
-13,892
Closed -$2.35M – 733
2025
Q1 		$2.35M Buy
+13,892
New +$2.28M 0.08% 128

Other funds holding DGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Caxton Associates (UK)'s DGX Position: Q4 2025 in Review

Caxton Associates (UK) sold out of Quest Diagnostics (DGX) in Q4 2025, closing a stake of 3,528 shares — an estimated $672K sold.

Caxton Associates (UK) first reported a position in DGX in Q1 2025 and held it in 2 quarters. The position peaked at $2.35M in Q1 2025. 1,048 funds tracked by Wall St. Rank hold DGX as of Q4 2025.

  • Caxton Associates (UK) reported no remaining Quest Diagnostics position as of Q4 2025 after selling out during the quarter.
  • Caxton Associates (UK) sold 3,528 Quest Diagnostics shares in Q4 2025, an estimated $672K.
  • Caxton Associates (UK) first reported a position in Quest Diagnostics in Q1 2025 and held it in 2 quarters.
  • Caxton Associates (UK)'s Quest Diagnostics position peaked at $2.35M in Q1 2025.
  • 1,048 funds tracked by Wall St. Rank held Quest Diagnostics as of Q4 2025.

Based on Caxton Associates (UK)'s 13F filing for Q4 2025, filed 13 Feb 2026.